MX2019013893A - Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. - Google Patents

Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.

Info

Publication number
MX2019013893A
MX2019013893A MX2019013893A MX2019013893A MX2019013893A MX 2019013893 A MX2019013893 A MX 2019013893A MX 2019013893 A MX2019013893 A MX 2019013893A MX 2019013893 A MX2019013893 A MX 2019013893A MX 2019013893 A MX2019013893 A MX 2019013893A
Authority
MX
Mexico
Prior art keywords
dengue viral
compounds
indoline derivatives
viral replication
substituted indoline
Prior art date
Application number
MX2019013893A
Other languages
English (en)
Inventor
Jean Maurice MERCEY Guillaume
Didier M Marchand Arnaud
Rudolf Romanie Kesteleyn Bart
François Bonfanti Jean-
Jean- Marie Bernard Raboisson Pierre
Alice Marie- Eve BARDIOT Dorothée
Coesemans Erwin
Michel Claude Fortin Jérôme
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2019013893A publication Critical patent/MX2019013893A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a derivados de indolina sustituidos, a metodos para prevenir o tratar infecciones virales por dengue mediante el uso de dichos compuestos y tambien se refiere a dichos compuestos para su uso como medicamento, más preferentemente, para su uso como medicamento para tratar o prevenir infecciones virales por dengue; la presente invencion se refiere ademas a composiciones farmaceuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como un medicamento, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invencion tambien se refiere a procesos para la preparacion de los compuestos.
MX2019013893A 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. MX2019013893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17172237 2017-05-22
PCT/EP2018/063028 WO2018215315A1 (en) 2017-05-22 2018-05-18 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
MX2019013893A true MX2019013893A (es) 2020-01-20

Family

ID=58745157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013893A MX2019013893A (es) 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.

Country Status (25)

Country Link
US (2) US11407715B2 (es)
EP (1) EP3630723B1 (es)
JP (1) JP7203764B2 (es)
KR (1) KR102625988B1 (es)
CN (1) CN110691773B (es)
AR (1) AR111878A1 (es)
AU (1) AU2018274100B2 (es)
BR (1) BR112019024195A2 (es)
CA (1) CA3060583A1 (es)
CL (1) CL2019003294A1 (es)
CO (1) CO2019012035A2 (es)
CR (1) CR20190530A (es)
EA (1) EA201992782A1 (es)
EC (1) ECSP19083640A (es)
ES (1) ES2929667T3 (es)
IL (1) IL270726B2 (es)
MA (1) MA48943A (es)
MX (1) MX2019013893A (es)
NI (1) NI201900119A (es)
PE (1) PE20200604A1 (es)
PH (1) PH12019502559A1 (es)
TW (1) TWI758480B (es)
UA (1) UA125407C2 (es)
UY (1) UY37742A (es)
WO (1) WO2018215315A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20180495A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Deribados de indol sustituidos como inhibidores de replicación viral del dengue
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
AU2017240076A1 (en) 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3630724B1 (en) 2017-05-22 2021-04-28 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177426B1 (en) 1997-10-27 2001-01-23 Eli Lilly And Company Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
BRPI0909985A2 (pt) 2008-06-03 2015-08-25 Siga Technologies Inc Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
ES2612731T3 (es) * 2008-08-19 2017-05-18 Janssen Pharmaceutica Nv Antagonistas de receptores al frío de mentol
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
AP2012006413A0 (en) 2010-01-15 2012-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
KR20140054425A (ko) * 2011-09-30 2014-05-08 후아웨이 테크놀러지 컴퍼니 리미티드 네트워크 발호 방법 및 장치
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
WO2015059212A1 (en) 2013-10-23 2015-04-30 Janssen R&D Ireland Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG11201606209PA (en) 2014-01-31 2016-08-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2721243T3 (es) 2014-10-01 2018-10-20
DK3201176T3 (en) 2014-10-01 2019-03-25 Janssen Pharmaceuticals Inc MONO OR DISUBSTITUTED INDEX DERIVATIVES AS INHIBITORS OF DENGUE VIRUS REPLICATION
TW201619130A (zh) 2014-10-01 2016-06-01 健生醫藥公司 作為登革熱病毒複製抑制劑之單-或二-取代吲哚
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
RU2761212C2 (ru) 2015-11-03 2021-12-06 Зоэтис Сервисиз Ллс Полимерные композиты, полученные по способу золь-гель, и их применение
EA201892216A1 (ru) * 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CR20180495A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Deribados de indol sustituidos como inhibidores de replicación viral del dengue
AR108012A1 (es) 2016-03-31 2018-07-04 Takeda Pharmaceuticals Co Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl
EP3436018A4 (en) 2016-04-01 2019-11-13 Signal Pharmaceuticals, LLC SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF
KR102411744B1 (ko) 2016-04-01 2022-06-21 바스프 에스이 바이시클릭 화합물
CA3177398A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
KR102584280B1 (ko) 2016-04-01 2023-10-04 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
JOP20170069B1 (ar) * 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MY201207A (en) 2016-04-01 2024-02-09 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
AU2017240076A1 (en) 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3630724B1 (en) 2017-05-22 2021-04-28 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
ES2929667T3 (es) 2022-11-30
UY37742A (es) 2018-11-30
CL2019003294A1 (es) 2020-03-20
PH12019502559A1 (en) 2021-01-25
NI201900119A (es) 2020-03-23
PE20200604A1 (es) 2020-03-10
CR20190530A (es) 2020-01-24
AR111878A1 (es) 2019-08-28
IL270726B2 (en) 2023-05-01
ECSP19083640A (es) 2019-11-30
CA3060583A1 (en) 2018-11-29
US11407715B2 (en) 2022-08-09
WO2018215315A1 (en) 2018-11-29
EA201992782A1 (ru) 2020-03-24
EP3630723B1 (en) 2022-08-24
CO2019012035A2 (es) 2020-01-17
CN110691773B (zh) 2023-06-23
JP7203764B2 (ja) 2023-01-13
TWI758480B (zh) 2022-03-21
IL270726A (en) 2020-01-30
TW201908291A (zh) 2019-03-01
US20220340522A1 (en) 2022-10-27
BR112019024195A2 (pt) 2020-06-23
KR20200009027A (ko) 2020-01-29
AU2018274100B2 (en) 2022-06-23
EP3630723A1 (en) 2020-04-08
IL270726B1 (en) 2023-01-01
KR102625988B1 (ko) 2024-01-16
JP2020520946A (ja) 2020-07-16
CN110691773A (zh) 2020-01-14
US20200255376A1 (en) 2020-08-13
MA48943A (fr) 2021-04-28
US11795149B2 (en) 2023-10-24
AU2018274100A1 (en) 2019-11-21
UA125407C2 (uk) 2022-03-02

Similar Documents

Publication Publication Date Title
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors